Paul Stoffels, company group chairman for Global R&D Pharmaceuticals at Johnson & Johnson, has a guest blog at CNBC about how "recent advances in science, genomics technologies, biomarkers, and drug development" have coalesced to offer the potential for personalized medicine. Using HIV drug development as an example, Stoffels makes the case that relying on diagnostic expertise throughout the process led not only to more targeted treatment, but also helped the pharma make better drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.